Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics

Brand Names


Austria: Beta Ophtiole; Belgium: Beta Ophtiole; France: Betanol; Germany: Betamann; Greece: Beta Ophtiole; Italy: Turoptin; Luxembourg: Betamann, Beta Ophtiole; Malta: Metipranolol; Netherlands: Beta Ophtiole; Poland: Betamann; Portugal: Beta Ophtiole; Slovakia: Trimepranol; UK: Metipranolol.

North America

Canada: OptiPranolol; USA: Metipranolol, OptiPranolol.

Drug combinations

Metipranolol and Pilocarpine


Metipranolol: C~17~H~27~NO~4~. Mw: 309.40. (1) Phenol, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-2,3,6-trimethyl-, (±)-, 1-acetate; (2)(±)-1-(4-Hydroxy-2,3,5-trimethylphenoxy)-3-(isopropylamino)-2-propanol 4-acetate. CAS-22664-55-7 (1990).

Pharmacologic Category

Antiglaucoma Agents, Miscellaneous; Nonselective β-Adrenergic Blocker. (ATC-Code: S01ED04).

Mechanism of action

Mechanism of action of metipranolol in reducing intraocular pressure appears to be via reduced production of aqueous humor.

Therapeutic use

Agent for lowering intraocular pressure in chronic open-angle glaucoma.

Pregnancy and lactiation implications

Use caution when administered during pregnancy or lactation.

Unlabeled use


Hypersensitivity to metipranolol or any component of the formulation. Bronchial asthma, sinus bradycardia, second- and third-degree AV block, cardiac failure, cardiogenic shock.

Warnings and precautions

Use caution with history of severe anaphylaxis to allergens. In general, patients with bronchospastic disease should not receive β-blockers. Use with caution in diabetes mellitus (might potentiate hypoglycemia and/or mask signs and symptoms), in compensated heart failure, in myasthenia gravis, in peripheral vascular disease (including Raynaud’s), and in history of psychiatric illness (may cause or exacerbate CNS depression). Some products may contain benzalkonium chloride which may be absorbed by soft contact lenses. β-blocker therapy should not be withdrawn abruptly (particularly in coronary artery disease). Systemic absorption and adverse effects might occur with ophthalmic use, including bradycardia and/or hypotension.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart